Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib as Adjuvant Treatment in the Recurrence of Hepatocellular Carcinoma
ChiCTR-OPC-16009725Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: recurrence-free survival. Started Oct 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OPC-16009725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16009725.